Apogee Therapeutics, Inc. Common Stock (NASDAQ:APGE) — Market Cap & Net Worth
Market Cap & Net Worth: Apogee Therapeutics, Inc. Common Stock (APGE)
Apogee Therapeutics, Inc. Common Stock (NASDAQ:APGE) has a market capitalization of $5.34 Billion ($5.34 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3458 globally and #1208 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apogee Therapeutics, Inc. Common Stock's stock price $86.19 by its total outstanding shares 61902733 (61.90 Million). Review how much debt does Apogee Therapeutics, Inc. Common Stock carry to assess the company's total debt and financial obligations.
Apogee Therapeutics, Inc. Common Stock Market Cap History: 2023 to 2026
Apogee Therapeutics, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows growth from $1.73 Billion to $5.34 Billion (74.16% CAGR).
Index Memberships
Apogee Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.22% | #81 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.01% | #389 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.31% | #54 of 263 |
Weight: Apogee Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Apogee Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apogee Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APGE by Market Capitalization
Companies near Apogee Therapeutics, Inc. Common Stock in the global market cap rankings as of June 17, 2026.
Key companies related to Apogee Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Apogee Therapeutics, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Apogee Therapeutics, Inc. Common Stock's market cap moved from $1.73 Billion to $ 5.34 Billion, with a yearly change of 74.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.34 Billion | +14.19% |
| 2025 | $4.67 Billion | +66.62% |
| 2024 | $2.80 Billion | +62.13% |
| 2023 | $1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Apogee Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.34 Billion USD |
| MoneyControl | $5.34 Billion USD |
| MarketWatch | $5.34 Billion USD |
| marketcap.company | $5.34 Billion USD |
| Reuters | $5.34 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more